NasdaqGS - Delayed Quote USD

Tilray Brands, Inc. (TLRY)

1.7200 0.0000 (0.00%)
At close: April 18 at 4:00 PM EDT
1.7200 0.00 (0.00%)
After hours: April 18 at 7:59 PM EDT
Loading Chart for TLRY
DELL
  • Previous Close 1.7200
  • Open 1.7400
  • Bid 1.7200 x 9900
  • Ask 1.7400 x 12700
  • Day's Range 1.6900 - 1.7900
  • 52 Week Range 1.5000 - 3.4000
  • Volume 30,151,136
  • Avg. Volume 29,292,030
  • Market Cap (intraday) 1.331B
  • Beta (5Y Monthly) 2.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4400
  • Earnings Date Apr 8, 2024 - Apr 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.36

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

www.tilray.com

1,600

Full Time Employees

May 31

Fiscal Year Ends

Recent News: TLRY

Performance Overview: TLRY

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TLRY
25.22%
S&P 500
5.06%

1-Year Return

TLRY
31.20%
S&P 500
20.71%

3-Year Return

TLRY
90.00%
S&P 500
19.73%

5-Year Return

TLRY
96.61%
S&P 500
72.77%

Compare To: TLRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TLRY

Valuation Measures

As of 4/19/2024
  • Market Cap

    1.33B

  • Enterprise Value

    1.59B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.65

  • Price/Book (mrq)

    0.40

  • Enterprise Value/Revenue

    2.14

  • Enterprise Value/EBITDA

    -12.35

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -47.35%

  • Return on Assets (ttm)

    -1.67%

  • Return on Equity (ttm)

    -9.69%

  • Revenue (ttm)

    743.25M

  • Net Income Avi to Common (ttm)

    -351.95M

  • Diluted EPS (ttm)

    -0.4400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    225.86M

  • Total Debt/Equity (mrq)

    14.41%

  • Levered Free Cash Flow (ttm)

    -14.88M

Research Analysis: TLRY

Analyst Price Targets

1.90
2.36 Average
1.7200 Current
4.00 High
 

Fair Value

Overvalued
% Return
1.7200 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Research Reports: TLRY

  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, Fair Isaac's upside fair; Initiating Coverage of GE Vernova; and US cable valuations have tumbled perhaps more than deserved; and Marvell Technology, Tilray Brands, and Yum China.

     
  • Analyst Report: Tilray Brands, Inc.

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

    Rating
    Neutral
    Price Target
     
  • Analyst Report: Tilray Brands, Inc.

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.

    Rating
    Bullish
    Price Target
     
  • Analyst Report: Tilray Brands, Inc.

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.

    Rating
    Neutral
    Price Target
     

People Also Watch